Fermion Technology, founded in 2015, is making strategic strides in the intersection of AI, Health Care, and Pharmaceutical industries. Their mission, captured in the slogan, "Harnessing AI to boost the efficiency of early-stage drug development through collaboration with CROs and pharmaceutical pioneers," underscores their innovative approach to drug development.
The company develops an AI-assisted platform aimed at enhancing the efficiency of small molecule drug development, a critical area of growth in the healthcare sector. Fermion Technology partners with Contract Research Organizations (CROs) and pharmaceutical firms to refine the early stages of drug creation, boosting efficiency and collaboration.
As of 18 July 2022, the startup secured a substantial CNY100.00M Series B investment from notable investors such as Panda Capital, Zhengxuan Investment, Challenjers Capital, and Iflytek, signaling strong confidence in their capabilities and growth potential.
